ReviR Therapeutics today announced a strategic investment from CureCMT to support the launch of a precision medicine platform for Charcot-Marie-Tooth disease (CMT). The platform will combine isogenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results